(Reuters) - Intellipharmaceutics International Inc said on Monday that the U.S. Food and Drug Administration declined to approve its long-acting opioid painkiller in its current form, backing its independent advisory panel that had raised concerns over the drug's abuse-deterrence capabilities.
No comments:
Post a Comment